TACE联合热消融治疗不可切除肝细胞癌的3期TORCH随机临床试验
这项在中国2个中心开展的开放标签3期随机试验纳入241例BCLC B期肝细胞癌患者,比较TACE联合后续热消融与单纯TACE。联合组中位PFS为17.7个月对7.3个月(HR 0.47,P<.001),中位OS为88.6个月对35.1个月(HR 0.50,P<.001)。
要点
- TACE联合热消融较单纯TACE显著延长PFS(17.7 vs 7.3个月,HR 0.47)。
- 联合组中位OS达88.6个月,单纯TACE组为35.1个月(HR 0.50)。
- 低至中度肿瘤负荷评分(≤6及6-12分)患者中PFS和OS均见临床意义改善。
核心结论
- 在肝局限性不可切除HCC患者中,TACE联合后续热消融较单纯TACE显示出更优的生存结局。
- 序贯TACE-消融可作为此类患者的一种可行治疗选择。
研究设计与样本
- 开放标签、3期TORCH随机临床试验,2015年5月至2024年8月在中国2个三级医疗中心开展。
- 纳入BCLC B期HCC患者,按1:1随机分配至TACE联合后续选择性射频消融组或单纯TACE组。
- 意向治疗人群共241例,TACE-消融组121例,单纯TACE组120例;数据截止2025年10月31日。
主要发现
- RECIST 1.1评估的中位PFS:TACE-消融组17.7个月(95%CI 11.4-23.1)vs 单纯TACE组7.3个月(95%CI 6.4-10.4),HR 0.47(95%CI 0.34-0.65),P<.001。
- 不可治疗PFS:TACE-消融组35.1个月 vs 单纯TACE组12.3个月,HR 0.40(95%CI 0.27-0.58),P<.001。
- 中位OS:TACE-消融组88.6个月(95%CI 43.1个月至不可估计)vs 单纯TACE组35.1个月(95%CI 25.4-45.5),HR 0.50(95%CI 0.34-0.73),P<.001。
- 低至中度肿瘤负荷评分(≤6分和6-12分)患者中观察到PFS和OS的临床意义改善。
- 3级和4级治疗相关不良事件:TACE-消融组23例(23.2%),单纯TACE组24例(18.3%)。
关键数值与推荐
- 主要终点为RECIST 1.1评估的PFS;次要终点包括OS、mRECIST评估的治疗反应和PFS、不可治疗PFS及安全性。
- 肿瘤负荷评分低于6分、6至12分、高于12分的患者数:TACE-消融组分别为34例(28.1%)、79例(65.3%)、8例(6.6%);单纯TACE组分别为31例(25.8%)、76例(63.3%)、13例(10.8%)。
临床怎么用
- 对于肝局限性不可切除的BCLC B期HCC,可考虑TACE后序贯热消融以改善PFS和OS。
- 低至中度肿瘤负荷评分患者可能从序贯TACE-消融中获益更明显。
局限性
- 开放标签设计。
- 仅在中国2个三级医疗中心开展。
- OS置信区间较宽(TACE-消融组上限不可估计)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transarterial chemoembolization (TACE) is the standard of care for liver-confined hepatocellular carcinoma (HCC) that is not amenable to curative treatment; however, TACE has demonstrated unsatisfactory survival benefits. OBJECTIVE: To evaluate whether combining TACE with subsequent thermal ablation improves clinical outcomes compared with TACE alone in patients with liver-confined unresectable HCC. DESIGN, SETTING, AND PARTICIPANTS: The open-label, phase 3 TORCH randomized clinical trial was conducted from May 2015 to August 2024 at 2 tertiary medical centers in China. Patients with Barcelona Clinic Liver Cancer stage B HCC were enrolled. The data cutoff was October 31, 2025. INTERVENTIONS: Patients were randomly assigned (1:1) to receive either TACE combined with subsequent selective radiofrequency ablation (TACE-ablation) or TACE alone. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS), assessed per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Secondary end points included overall survival (OS), treatment response and PFS per modified RECIST, untreatable PFS, and safety. RESULTS: Among 241 patients included in the intention-to-treat population, 121 received TACE-ablation (median [IQR] age, 59.0 [51.0-66.0] years; 108 [89.3%] male), and 120 received TACE alone (mean [IQR] age, 58.0 [50.0-64.0]; 106 [88.3] male). The number of patients with 6-and-12 tumor burden scores of lower than 6, 6 to 12, and more than 12 points were 34 (28.1%), 79 (65.3%), and 8 (6.6%) in the TACE-ablation group and 31 (25.8%), 76 (63.3%), and 13 (10.8%) in the TACE alone group, respectively. At the data cutoff, the median PFS per RECIST, version 1.1, was 17.7 months (95% CI, 11.4-23.1 months) in the TACE-ablation group vs 7.3 months (95% CI, 6.4-10.4 months) in the TACE alone group (hazard ratio [HR], 0.47; 95% CI, 0.34-0.65; P < .001). TACE-ablation also resulted in statistically significant prolonged untreatable PFS compared with TACE (35.1 months vs 12.3 months; HR, 0.40; 95% CI, 0.27-0.58; P < .001). Median OS was 88.6 months (95% CI, 43.1 months to not estimable) with TACE-ablation and 35.1 months (95% CI, 25.4-45.5 months) with TACE alone (HR, 0.50; 95% CI, 0.34-0.73; P < .001). Clinically meaningful improvements in both PFS and OS were observed in patients with low to moderate tumor burden scores (≤6 and 6-12 points). Grade 3 and 4 treatment-related adverse events occurred in 23 patients (23.2%) in the TACE-ablation group and 24 (18.3%) in the TACE alone group. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, TACE combined with subsequent thermal ablation demonstrated superior survival outcomes than TACE alone in patients with liver-confined unresectable HCC. Sequential TACE-ablation could serve as a feasible treatment option for such patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02435953.
引用
- Lyu N, Yi JZ, Wu XT, et al. Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42530948. doi:10.1001/jamaoncol.2026.2366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。